<DOC>
	<DOCNO>NCT00390091</DOCNO>
	<brief_summary>The primary purpose study assess safety pharmacodynamic effect LJP 394 dose 100 mg , 300 mg 900 mg anti-dsDNA antibody level patient SLE .</brief_summary>
	<brief_title>Study LJP 394 ( Abetimus Sodium ) Lupus Patients</brief_title>
	<detailed_description>STUDY NOW INCORPORATED INTO PHASE 3 STUDY NCT00089804 .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Males females 12 70 year old . Diagnosis Systemic Lupus Erythematosus ( SLE ) Females must nonpregnant nonlactating . Females must agree use adequate birth control method course study . Ability weekly intravenous ( IV ) administration study drug . Prior exposure abetimus sodium within 6 month prior screen . Patients stable medication 30 day prior screen . Patients acute chronic infection .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Lupus</keyword>
	<keyword>Nephritis</keyword>
	<keyword>Kidney</keyword>
	<keyword>SLE</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Nephritis , Lupus</keyword>
</DOC>